Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;37(11):1043-1046.
doi: 10.1038/s41371-023-00831-z. Epub 2023 Apr 19.

Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors

Sean Tan  1   2 , Ella Spear  3 , Nikhita Sane  3 , Adam J Nelson  4   3 , Nitesh Nerlekar  4   3 , Eva Segelov  5 , Stephen J Nicholls  4   3
Affiliations

Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors

Sean Tan et al. J Hum Hypertens. 2023 Nov.

Abstract

Immune checkpoint inhibitors (ICI) are cancer therapies that have been associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). Blood pressure (BP) measurements are routinely performed during day oncology center visits for administration of ICI therapy but are often not assessed temporally to screen and monitor hypertension, which could independently increase the risk of ASCVD in cancer survivorship. This study reports the feasibility of using serial BP measurements from routine visits to day oncology center to diagnose and monitor hypertension control in cancer patients receiving ICIs.

PubMed Disclaimer

Conflict of interest statement

SJN has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Eli Lilly, Esperion, Resverlogix, Novartis, InfraReDx, and Sanofi-Regeneron and is a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron and Novo Nordisk. All other authors do not have any disclosures to declare.

References

    1. Tan S, Day D, Nicholls SJ, Segelov E. Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: cardiooncology state-of-the-art review. JACC CardioOncol. 2022;4:579–97. doi: 10.1016/j.jaccao.2022.09.004. - DOI - PMC - PubMed
    1. Vuong JT, Stein-Merlob AF, Nayeri A, Sallam T, Neilan TG, Yang EH. Immune checkpoint therapies and atherosclerosis: mechanisms and clinical implications: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79:577–93. doi: 10.1016/j.jacc.2021.11.048. - DOI - PMC - PubMed
    1. Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142:2299–311. doi: 10.1161/CIRCULATIONAHA.120.049981. - DOI - PMC - PubMed
    1. Dolladille C, Akroun J, Morice PM, Dompmartin A, Ezine E, Sassier M, et al. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J. 2021;42:4964–77. doi: 10.1093/eurheartj/ehab618. - DOI - PubMed
    1. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133:1104–14. doi: 10.1161/CIRCULATIONAHA.115.020406. - DOI - PMC - PubMed

Publication types

Substances